Literature DB >> 23600628

Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.

Ambra Gianotti1, Raffaella Melani, Emanuela Caci, Elvira Sondo, Roberto Ravazzolo, Luis J V Galietta, Olga Zegarra-Moran.   

Abstract

In the respiratory system, Na(+) absorption and Cl(-) secretion are balanced to maintain an appropriate airway surface fluid (ASF) volume and ensure efficient mucociliary clearance. In cystic fibrosis (CF), this equilibrium is disrupted by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in the absence of functional CFTR-dependent Cl(-) secretion. The consequences of defective Cl(-) transport are worsened by the persistence of Na(+) absorption, which contributes to airway surface dehydration. We asked whether normal ASF can be restored to an equal extent by recovering Cl(-) secretion from mutated CFTR or by reducing Na(+) absorption. This is highly relevant in the selection of the best strategy for the treatment of patients with CF. We analyzed the ASF thickness of primary cultured bronchial CF and non-CF epithelia after silencing the epithelial Na(+) channel (ENaC) with specific short, interfering RNAs (siRNAs) and after the pharmacological stimulation of CFTR. Our results indicate that (1) single siRNAs complementary to ENaC subunits are sufficient to reduce ENaC transcripts, Na(+) channel activity, and fluid transport, but only silencing both the α and β ENaC subunits at the same time leads to an increase of ASF (from nearly 7 µm to more than 9 µm); (2) the ASF thickness obtained in this way is about half that measured after maximal CFTR stimulation in non-CF epithelia (10-14 µm); and (3) the pharmacological rescue of mutant CFTR increases the ASF to the same extent as ENaC silencing. Our results indicate that CFTR rescue and ENaC silencing both produce a significant and long-lasting increase of airway hydration in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600628     DOI: 10.1165/rcmb.2012-0408OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  13 in total

1.  Small molecule-facilitated anion transporters in cells for a novel therapeutic approach to cystic fibrosis.

Authors:  Michele Fiore; Claudia Cossu; Valeria Capurro; Cristiana Picco; Alessandra Ludovico; Marcin Mielczarek; Israel Carreira-Barral; Emanuela Caci; Debora Baroni; Roberto Quesada; Oscar Moran
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

2.  Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers.

Authors:  Debora Baroni; Olga Zegarra-Moran; Agneta Svensson; Oscar Moran
Journal:  Eur Biophys J       Date:  2014-04-26       Impact factor: 1.733

3.  High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel.

Authors:  Valeria Tomati; Emanuela Pesce; Emanuela Caci; Elvira Sondo; Paolo Scudieri; Monica Marini; Felice Amato; Giuseppe Castaldo; Roberto Ravazzolo; Luis J V Galietta; Nicoletta Pedemonte
Journal:  J Biol Chem       Date:  2017-11-20       Impact factor: 5.157

Review 4.  The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.

Authors:  Ren-Jay Shei; Jacelyn E Peabody; Niroop Kaza; Steven M Rowe
Journal:  Curr Opin Pharmacol       Date:  2018-10-16       Impact factor: 5.547

Review 5.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Authors:  Marcus A Mall; Nicole Mayer-Hamblett; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

6.  Emphysema Is Common in Lungs of Cystic Fibrosis Lung Transplantation Patients: A Histopathological and Computed Tomography Study.

Authors:  Onno M Mets; Suzan M Roothaan; Inez Bronsveld; Bart Luijk; Ed A van de Graaf; Aryan Vink; Pim A de Jong
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

7.  Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy.

Authors:  Claudia Cossu; Michele Fiore; Debora Baroni; Valeria Capurro; Emanuela Caci; Maria Garcia-Valverde; Roberto Quesada; Oscar Moran
Journal:  Front Pharmacol       Date:  2018-08-07       Impact factor: 5.810

8.  The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.

Authors:  Min He; Shanshan Liu; Sachith Gallolu Kankanamalage; Mark D Borromeo; Luc Girard; Adi F Gazdar; John D Minna; Jane E Johnson; Melanie H Cobb
Journal:  Transl Oncol       Date:  2018-02-02       Impact factor: 4.243

9.  Lack of Kcnn4 improves mucociliary clearance in muco-obstructive lung disease.

Authors:  Génesis Vega; Anita Guequén; Amber R Philp; Ambra Gianotti; Llilian Arzola; Manuel Villalón; Olga Zegarra-Moran; Luis Jv Galietta; Marcus A Mall; Carlos A Flores
Journal:  JCI Insight       Date:  2020-08-20

10.  Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung.

Authors:  Aristides D Tagalakis; Mustafa M Munye; Rositsa Ivanova; Hanpeng Chen; Claire M Smith; Ahmad M Aldossary; Luca Z Rosa; Dale Moulding; Josephine L Barnes; Konstantinos N Kafetzis; Stuart A Jones; Deborah L Baines; Guy W J Moss; Christopher O'Callaghan; Robin J McAnulty; Stephen L Hart
Journal:  Thorax       Date:  2018-05-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.